GRIFOLS S.A.
Grifols operates as a plasma therapeutic company globally. It provides various products for treating conditions like immunodeficiencies, liver cirrhosis, and hemophilia. The company also markets diagnostic testing equipment and biological products. Grifols manufactures and sells plasma to third parties and conducts research activities. Its pharmaceutical product portfolio includes Yimmugo PID and ITP, among others. The company has several products in various stages of clinical development, including Phase IV, III, and II.
Overview
Strengths
- Price to book ratio (1.41) is lower than the sector mean (8.32).
- EV/EBITDA (10.63) is lower than the sector mean (21.51).
- EV/EBIT (15.56) is lower than the sector mean.
- Price to free cash flow (15.68) is lower than the sector mean.
- Strong EBITDA Margin of 21.23%.
Weaknesses
- With a depreciation Potential of -53.29%, based on our fundamental analysis, it suggests the stock may be overvalued.
- The company has high debt. Net Debt to EBITDA Ratio (5.20) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (6.08%) is significantly lower than the sector mean (16.32%).
Key Financial Data
| Indicator | Value |
|---|
| PER | 52.1 |
| EV/EBITDA | 10.5 |
| Price/Free Cash Flow' | 15.4 |
| ROIC | 6.1% |
| Net Debt/EBITDA | 5.2 |